EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Gene Expression Tumor Signature Optimizing Partial Area‐Under‐the‐Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer

Travis A Gerke, Svitlana Tyekucheva, Konrad H Stopsack, Christopher J Sweeney iD, Rosina T Lis, Elizabeth N Westling iD, Massimo Loda, Meir J Stampfer, Kathryn L Penney, Giovanni Parmigiani, Lorelei A Mucci

The Prostate · 2026-06 · 86 (9) · 1075-1082

DOI: 10.1002/pros.70189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, online erschienen am 29.04.2026. Verfasst von Travis A Gerke und 10 weiteren Autor:innen. Beteiligte Einrichtung: Prostate Cancer Clinical Trials Consortium, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor, Transcriptome. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, DF/HCC Specialized Programs in Research Excellence (SPORE) in Prostate Cancer, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

A key clinical challenge in prostate cancer is the identification and validation of biomarkers with high specificity for indolent long‐term outcomes. We applied a novel statistical method to identify tumor transcriptomic biomarkers that optimally predicted patients with low metastatic potential.

Methods

Using tumor whole‐transcriptome data from the Health Professionals Follow‐up Study (HPFS, discovery set) and Physicians' Health Study (PHS, validation set), we compared patients who died of prostate cancer or developed metastases (“lethal,” n = 113) and patients with > 8 years of metastasis‐free survival (“indolent,” n = 291). Whole transcriptome tumor gene expression data were generated using an Affymetrix array. We applied a novel method for optimizing a partial area under the curve (pAUC) that up‐weighted indolent cases with a predefined 80%–100% specificity. This method leverages weighted logistic lasso regression, with weights chosen via cross‐validation to reduce overfitting.

Results

Median age at cancer diagnosis was 66 years; median follow‐up for outcomes was 14 years. We identified a 40‐gene transcriptome signature of indolent prostate cancer, which, compared to Gleason grade groups, improved the pAUC over the predefined 80%–100% specificity range by 1.72‐fold ( p < 0.001) and improved overall AUC from 0.85 to 0.93 ( p < 0.001). The signature improved positive predictive value for indolent tumors > 2‐fold with minimal decrease in negative predictive value. Importantly, the 40‐gene signature showed high discrimination among intermediate Gleason 7 tumors (Grade groups 2 and 3, AUC 0.88, 95% CI: 0.79–0.95).

Conclusion

Incorporating pAUC into prognostic signature development improved identification of prostate tumors with low risk of metastatic potential. Its clinical application may help reduce overtreatment and overdiagnosis of indolent prostate cancers, and the pAUC may be relevant beyond prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBiomarkers, TumorTranscriptomeMaleHumansArea Under CurveGene Expression ProfilingAgedGene Expression Regulation, NeoplasticFollow-Up Studies

Stichwörter der Autor:innen

gene expressionindolent prostate cancerpartial area‐under‐the‐curveprognostic biomarkers

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Prostate Cancer Clinical Trials Consortium, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Department of Epidemiologic Methods and Etiologic Research, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
  • South Australian Immunogenomics Cancer Center, University of Adelaide, Adelaide, Australia.

ORCID-Profile: Christopher J Sweeney, Elizabeth N Westling

Förderung

  • NCI NIH HHS
  • DF/HCC Specialized Programs in Research Excellence (SPORE) in Prostate Cancer
  • National Cancer Institute

Zitieren

APA

Gerke, T. A., Tyekucheva, S., Stopsack, K. H., Sweeney, C. J., Lis, R. T., Westling, E. N., Loda, M., Stampfer, M. J., Penney, K. L., Parmigiani, G., & Mucci, L. A. (2026). A Gene Expression Tumor Signature Optimizing Partial Area‐Under‐the‐Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer. The Prostate, 86(9), 1075-1082. https://doi.org/10.1002/pros.70189

Vancouver

Gerke TA, Tyekucheva S, Stopsack KH, Sweeney CJ, Lis RT, Westling EN, et al. A Gene Expression Tumor Signature Optimizing Partial Area‐Under‐the‐Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer. The Prostate. 2026;86(9):1075-1082. doi:10.1002/pros.70189

BibTeX
@article{Gerke2026,
  author = {Gerke, Travis A and Tyekucheva, Svitlana and Stopsack, Konrad H and Sweeney, Christopher J and Lis, Rosina T and Westling, Elizabeth N and Loda, Massimo and Stampfer, Meir J and Penney, Kathryn L and Parmigiani, Giovanni and Mucci, Lorelei A},
  title = {A Gene Expression Tumor Signature Optimizing Partial Area‐Under‐the‐Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer},
  journal = {The Prostate},
  year = {2026},
  volume = {86},
  number = {9},
  pages = {1075--1082},
  doi = {10.1002/pros.70189}
}
Kostenlos starten →